Pepti: August 2026 Investigation and Current Review

Pepti now has a graded review: 78.8/100, grade C+. Read the current Pepti scorecard for the six factor scores and the full caveats.

Current provider record

Semaglutide: $109 per 28 days (all-in; billing can fall twice in one calendar month). Tirzepatide: $179 per 28 days (all-in; billing can fall twice in one calendar month).

Coverage recorded in the graded review: All 50 states plus Washington, D.C.. The provider record's merchant-verification date is 2026-09-01. This article was reconciled with that existing record on October 6, 2026; this is not a new merchant verification. The August findings below do not establish today's checkout price or resolve every previously documented discrepancy.

The current review records these caveats: The site prints $79 on its own semaglutide cost page and $109 on the same page, and $149 against $179 for tirzepatide; the figures that transact are $109 and $179. The product pages label the figure an all-in monthly price while the billing terms set the cycle at 28 days and warn it can bill twice in one calendar month.

Historical investigation — August 7, 2026

The following investigation records what our August pass found. Its prices, availability, named providers and policies describe that pass, not current offers. Each section is dated to keep those historical observations separate from the current record above. The original citations remain attached to the observations they supported.

The August 7, 2026 review of Pepti (hellopepti.com) found conflicting semaglutide prices, state-availability statements and payment timing. This historical investigation preserves those unresolved questions. Pepti now has a separate graded review, linked above; the later grade does not itself settle the earlier discrepancies.

August 2026: Advertised prices in the August review

Injectable semaglutide is $99 a month and injectable tirzepatide is $199 a month, flat at every titration dose, with a one-time purchase option at $124 and $249 respectively. The subscription is cancel-anytime with no minimum term and a pause of up to 90 days. Around those two sit oral semaglutide at $249, oral tirzepatide at $399, GLP-1 oral drops at $239, a GLP-1/GIP drop at $349, and two explicitly low-dose "longevity microdose" SKUs at $149 and $229.

Dose-based step-ups can change the cost as treatment continues. Compare starting prices with maintenance-dose prices and payment terms; the cost-value mark does not establish an equivalent-dose treatment total. See how the WeighScore is calculated for what the score covers. If $99 holds at 2.4 mg, it is the cheapest rung of the seven companies in this pass — though graded providers in our own ranking publish month-to-month semaglutide below it, so this would not be the cheapest number on the site.

August 2026: The unresolved finding

The August review also found a dose-based price list in the site's published data that differed from the displayed offer: semaglutide at $299 for 0.25 mg, $349 for 0.5 mg, $399 for 1.0 mg and $449 for 2.4 mg; tirzepatide at $349, $399, $449 and $549 across its ladder. The company's cost page instead advertised one flat monthly semaglutide price of $99 at every dose.

The August review did not establish which price would apply at checkout, whether the dose-based list remained applicable, or which offer a patient would qualify for. The $99 headline and the higher dose-based figures remain an unresolved discrepancy, not interchangeable quotes.

Anyone shortlisting Pepti on price should get the maintenance-dose figure in writing before the first charge. That is good practice with any provider — it is the first item in our six-point checklist — and here it is the specific question that decides whether the offer is what it appears to be.

August 2026: The 36-versus-50-state discrepancy

Four separate surfaces on the site — the shipping page, the state-availability page, the providers page and the homepage title — publish the same list of 36 states. The terms of service say the services are available in 50. Those conflicting statements did not establish eligibility for a particular patient; confirm the current medication and destination state before enrolling. At-home blood panels ship more broadly than the medication does.

August 2026: When your card is charged

The how-it-works page says you pay nothing until a physician approves your treatment. The refund policy says payment is collected at checkout, before a licensed provider reviews your intake. The August pages therefore disagreed on the first charge. The refund policy described a denial refund within five to ten business days; the actual payment timing was not confirmed through a purchase. Nothing is refundable once medication ships, and cancellation is not prorated.

That is the second internal contradiction on this site, and the pattern matters more than either instance. Contract terms carry only 8% of a WeighScore, but they are the dimension where a company's two surfaces disagreeing tells you something the marketing copy never will.

August 2026: Named clinicians and unresolved identity checks

The August pages named Dr. Gene Lee, MD, medical director, family medicine, licensed in 26 named states; Dr. Laeeq Butt, MD MBA, chief medical officer, internal medicine, licensed in 15. Those pages included bios describing education and board certifications; this investigation did not independently verify those claims.

The published names support registry searches by name even without an NPI on the merchant page. We did not establish an exact registry match or the identity of the assigned treating clinician. An NPI is not proof of licensure or credentials; a state-board license check is separate. The dispensing pharmacy is never named at all; the site describes "independent FDA-registered 503A or 503B compounding pharmacies" and stops there. Our fulfillment dimension asks which pharmacy fills the vial, and that question has no answer here. Why it matters is in is compounded semaglutide legit and safe? The legal entity is pepti LLC at a Newark, Delaware address that is a registered-agent suite rather than an operating site.

August 2026: The shelf around the GLP-1s

The August catalog listed roughly 68 items, including peptides, nasal sprays, an anti-aging line and blood panels at $199. Historical listings included BPC-157 at $209 a month, sermorelin and tesamorelin at $189 each, NAD+ at $159 to $219 depending on route, a sleep peptide at $189.

Listing a product does not establish its approval, effectiveness or suitability. The August catalog also included retatrutide, melanotan II and IGF-1 LR3. Retatrutide has no FDA approval in any form, in any jurisdiction. This site does not treat any of those three as a recommendable option and never will, and a reader comparing GLP-1 programs should understand that a broad shelf is not automatically a feature. If your interest is the approved molecules and how they differ, semaglutide vs. tirzepatide is the comparison that is actually supported by trial data.

August 2026: The regulatory screen

The FDA's live warning-letter index returned no company-column match for Pepti, for its legal entity, or for the compounding framework it names, in August 2026. The same pass returned a known February 2026 letter for an unrelated telehealth seller used as a positive control, so the zero is a real zero rather than a query that failed quietly. Worth noting what the neighboring rows look like: a search on the company's own name-stem returns a long list of peptide sellers that do carry letters. Pepti is not among them.

August 2026: Questions left by the original investigation

The unresolved questions were the maintenance-dose checkout price behind the $99-versus-$399 discrepancy, and exact clinician identity and assignment supported by registry and state-board records. Those were unresolved questions at the end of the August pass. The contemporary comparisons were Trellis Vitality at $150 and Auren Rx at $199; those figures belong to that historical comparison. See the current Pepti review for its later filed pricing and grade.